TCT 2023 Late-Breaking Science Collection

Published: 09 January 2024

  • Views:

    Views Icon 250
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations. 

Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data. 

About the episode

TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic.

The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid aortic anatomy and severe aortic stenosis, who are at low-risk for SAVR. All patients enrolled in the trial were treated with the system and were followed up at pre and post-procedure, discharge, 30 days, 1 year, and annually through 10 years. These results show the four-year outcomes of this patient group.

Findings suggest that in low-risk patients, the Evolut TAVR system had lower reported rates of death or disabling stroke compared to state-of-the-art surgery that are diverging each year to 4 years, as well as superior hemodynamics when compared to SAVR. 

Interview Questions:

  1. What are the current unmet needs of TAVR Patients?
  2. Could you tell us a bit about the Medtronic TAVR System, including its unique features?
  3. What was the study design and patient population?
  4. What are the key findings?
  5. What are your take-home messages?
  6. What further study is still required, and what are the next steps?

Recorded remotely from Texas, 2023.

Editor: Jordan Rance
Video Specialist: Tom Green

Faculty Biographies

Michael J Reardon

Michael J Reardon

Dr Michael J. Reardon holds the position of Clinical Professor of Cardiothoracic Surgery at MD Anderson Cancer Center and created the multi-institution, multidisciplinary cardiac tumor team with HMH and MDA. 

He has served as elected president of the medical staff for the HMH and received numerous awards including the Overstreet Award and Noon Award. He currently holds the Allison Family Distinguished Chair of Cardiovascular Research and divides his time between building innovative clinical, research and educational programs.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.